论文部分内容阅读
目的研究术后复发或转移的结、直肠癌患者对全身热疗联合FOLFOX7方案的耐受性,并观察疗效和副作用。方法回顾性分析广州医学院附属肿瘤医院2002年6月至2005年7月的18例晚期结、直肠癌患者,在全身麻醉状态下用ET-SPACE-Ⅰ全身热疗系统联合FOLFOX7方案进行全身热化疗的临床资料,并与同期23例采用FOLFOX7化疗及对症治疗的晚期结、直肠癌患者进行对照。结果观察组患者的生存质量的改善优于对照组,差异有统计学意义；有效率较对照组高,且有1例为完全缓解,差异有统计学意义；观察组化疗毒副反应未增加。结论采用ET-SPACE-Ⅰ全身热疗系统联合FOLFOX7方案进行全身热化疗安全性好,控温精确,治疗晚期结、直肠癌值得推广应用。
Objective To study the tolerability of systemic hyperthermia combined with FOLFOX7 regimen in patients with recurrent or metastatic recurrent or rectal cancer and to observe the efficacy and side effects. Methods Retrospective analysis of 18 patients with advanced colorectal cancer and rectal cancer from June 2002 to July 2005 in Guangzhou Medical College Affiliated Cancer Hospital. Systemic fever was performed under general anesthesia with ET-SPACE-I whole body hyperthermia system combined with FOLFOX7 regimen. The clinical data of chemotherapy were compared with 23 cases of advanced colorectal cancer patients treated with FOLFOX7 chemotherapy and symptomatic treatment in the same period. Results The quality of life of the observation group was better than that of the control group. The difference was statistically significant. The effective rate was higher than that of the control group, and 1 case was complete remission. The difference was statistically significant. The side effects of chemotherapy in the observation group did not increase. Conclusion The use of ET-SPACE-I whole body hyperthermia system combined with FOLFOX7 regimen for systemic thermochemotherapy has good safety, precise temperature control, and treatment of advanced node and rectal cancer deserves popularization and application.